Further validation was performed in the GEO dataset and our cohort, the results showed that patients with high CSE and TNFSF14 expression in HCC showed less portal invasion, lower BCLC stages and longer survival and disease-free time compared with lower TNFSF14 expression patients. The gene discussed is TNFSF14; the disease is hepatocellular carcinoma.